ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 716

Radiographic Progression and Changes in Inflammation and Structural Damage on Serial MRI Examinations over 5 Years in Patients with Ankylosing Spondylitis Treated with TNF-Alpha Inhibitors

Susanne Juhl Pedersen1, Ulrich Weber2, Roula Said Nahal3, Inge Juul Sorensen1, Anne Gitte Loft4, Niels Tvede1, Gina Kollerup1, Lars Juul1, Gorm Thamsborg1, Ole Rintek Madsen1, Jakob M. Møller5, Lone Balding6, Anne Grethe Jurik7 and Mikkel Østergaard8, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 2Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, 3Ambroise Paré Hospital, Boulogne-Billancourt, France, 4Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, 5Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark, 6Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, 7Dept. of Radiology, Aarhus University Hospital, Aarhus, Denmark, 8Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Ankylosing spondylitis (AS), MRI, radiography and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Only few studies have investigated long-term radiographic progression in the spine of patients with ankylosing spondylitis (AS). Moreover, no studies have reported changes in MRI lesions of inflammation and structural damage in the sacroiliac joints (SIJs) and spine assessed with annually repeated scans over 5 years. The aim was to investigate radiographic progression and evolution of MRI inflammation and structural lesions during treatment with TNFα inhibitors over 5 years assessed with serial examinations.

Methods: The study included 33 patients with AS followed for 5 years. All patients had participated in the BIOSPA study(1), which included 60 patients initiating treatment with TNFα inhibitor (infliximab, etanercept or adalimumab). Spinal radiographs were obtained 4 times (at week 0, 46, year 3 and 5) and MRIs of the SIJs and the lower spine (Th9-S1) were acquired 7 times (at week 0, 22 and 46 and annually to year 5), respectively. The images were evaluated in known time order without other information available. The SPARCC Sacroiliac and Spine Inflammation Index and Structural Scores (SSS) (2) and the Canada-Denmark (CanDen) scores of inflammation, fat(3), erosions and new bone formation (4,5) were used for the MRI evaluations. The modified Stoke AS Spine Score (mSASSS)(6) were used for the evaluation of the radiographs.

Results: During 5 years of TNFα inhibitor treatment, mSASSS increased significantly at all study visits (p<0.01) (Figure 1), and the structural MRI spine score SASSS increased significantly from year 2 (p<0.05). The mSASSS progression rate was significantly lower from week 46 to year 3 (0.45 units/year) than from week 0 to 46 (1.71 unit/year), whereas there was no difference in the progression rate from week 0 to 46 versus year 3 to 5 (0.66 units/year, p=0.055). MRI inflammation decreased significantly in SIJ (p<0.05) and spine from week 22 (p<0.01, except for year 5), together with a significant decrease of SIJ erosion from week 46 (p<0.05) and throughout the study. Conversely, the SIJ and spinal MRI fat (p<0.05) and SIJ ankylosis scores increased significantly from week 22 (p<0.05). Only minor changes were observed for SIJ backfill and spine erosion score.

Conclusion: Radiographic progression decreased significantly after the first year of treatment with TNFα inhibitor. Spine and SIJ MRI inflammation and structural scores changed significantly short after initiation of treatment, and thereafter the scores remained statistically unchanged except. References: 1. Pedersen et al. Ann Rheum Dis ; 2. Maksymowych et al. J Rheumatol 2014; 3. Pedersen et al. Arthritis Res Ther 2014; 4. Lambert et al. J Rheumatol 2009 5. Østergaard et al. J Rheumatol 2009; 6. Averns HL et al. Br J Rheumatol 1996


Disclosure: S. J. Pedersen, AbbVie, 2,MDS, 2; U. Weber, None; R. Said Nahal, None; I. J. Sorensen, None; A. G. Loft, MSD, UCB, AbbVie, Pfizer., 8; N. Tvede, None; G. Kollerup, None; L. Juul, None; G. Thamsborg, None; O. Rintek Madsen, None; J. M. Møller, None; L. Balding, None; A. G. Jurik, None; M. Østergaard, None.

To cite this abstract in AMA style:

Pedersen SJ, Weber U, Said Nahal R, Sorensen IJ, Loft AG, Tvede N, Kollerup G, Juul L, Thamsborg G, Rintek Madsen O, Møller JM, Balding L, Jurik AG, Østergaard M. Radiographic Progression and Changes in Inflammation and Structural Damage on Serial MRI Examinations over 5 Years in Patients with Ankylosing Spondylitis Treated with TNF-Alpha Inhibitors [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/radiographic-progression-and-changes-in-inflammation-and-structural-damage-on-serial-mri-examinations-over-5-years-in-patients-with-ankylosing-spondylitis-treated-with-tnf-alpha-inhibitors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/radiographic-progression-and-changes-in-inflammation-and-structural-damage-on-serial-mri-examinations-over-5-years-in-patients-with-ankylosing-spondylitis-treated-with-tnf-alpha-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology